MeiraGTx Holdings Appoints Director Alan M. Sebulsky

What Happened
MeiraGTx Holdings plc announced on Sept. 23, 2026 (filed via Form 8-K) that the Board appointed Alan M. Sebulsky as a Class I director effective Sept. 23, 2026. His term runs until the Company’s 2028 annual meeting when Class I directors are up for re‑election. Mr. Sebulsky was added to the Science and Technology Committee and was recommended by the Company’s Nominating and Corporate Governance Committee and senior management.

Key Details

• Appointment effective: September 23, 2026; term expires at the 2028 annual meeting.
• Committee assignment: Member of the Science and Technology Committee.
• Background: Managing Member of Apothecary Capital LLC (since April 2026); previously Partner and Portfolio Manager at Adage Capital Management (July 2012–April 2026); earlier roles at BBT Capital and Lincoln Capital Management; current board member of Parabilis Medicines; past director at Jazz Pharmaceuticals PLC and Arrow International.
• Compensation & governance: Eligible for the Company’s Non‑Employee Director Compensation Program and expected to sign the standard indemnification agreement. The filing states there are no related‑party transactions and no special arrangements led to his selection.
• Disclosure: Appointment announced by press release filed as Exhibit 99.1 to the Form 8‑K.

Why It Matters
This is a board-level governance change that adds a director with extensive investment and biopharmaceutical portfolio experience. For investors, such appointments can affect oversight of strategy, R&D priorities, and capital allocation decisions—especially given his assignment to the Science and Technology Committee. The filing lists standard compensation and indemnification terms and confirms no related‑party issues, which are routine but relevant governance details.